MARKET

IVVD

IVVD

Invivyd
NASDAQ
0.6020
-0.0146
-2.37%
After Hours: 0.5650 -0.037 -6.15% 16:48 10/29 EDT
OPEN
0.6100
PREV CLOSE
0.6166
HIGH
0.6352
LOW
0.5726
VOLUME
3.08M
TURNOVER
--
52 WEEK HIGH
3.070
52 WEEK LOW
0.5277
MARKET CAP
177.44M
P/E (TTM)
-1.6118
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IVVD last week (1019-1023)?
Weekly Report · 3d ago
Invivyd presents measles antibody candidate VMS063 data at IDWeek 2026
TipRanks · 10/21 13:11
Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants
Benzinga · 10/21 11:12
Weekly Report: what happened at IVVD last week (1012-1016)?
Weekly Report · 10/19 09:37
Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome
Benzinga · 10/14 11:05
Weekly Report: what happened at IVVD last week (1005-1009)?
Weekly Report · 10/12 09:39
Weekly Report: what happened at IVVD last week (0928-1002)?
Weekly Report · 10/05 09:39
Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
NASDAQ · 10/02 16:13
More
About IVVD
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Webull offers Invivyd Inc stock information, including NASDAQ: IVVD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IVVD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IVVD stock methods without spending real money on the virtual paper trading platform.